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INTRODUCTION
Since 2006, Medicare beneficiaries have had access to prescription drug coverage offered by
private plans, either stand-alone prescription drug plans (PDPs) or Medicare Advantage prescription
drug plans (MA-PD plans). Medicare drug plans (also referred to as Part D plans) receive payments
from the government to provide Medicare-subsidized drug coverage to enrolled beneficiaries.  Part
D plans are required to offer either a defined standard benefit or one that is equal in value, and
may also offer an enhanced benefit.1 Medicare drug plans must meet defined requirements, but
may vary in terms of premiums, benefit design, gap coverage, formularies, and utilization
management rules.  Today, more than 25 million Medicare beneficiaries are enrolled in Medicare
drug plans, including 17.4 million in stand-alone prescription drug plans and 8.0 million in Medicare
Advantage drug plans.2
This report synthesizes findings from a series of Medicare Part D 2008 Data Spotlights that
documents the scope and generosity of drug coverage available to Medicare beneficiaries under
Part D plans, and changes in drug coverage and costs since 2006. It presents key findings related
to Medicare drug plan premiums, the coverage gap, benefit design and cost sharing, the specialty
tier, formularies and utilization management.3 The analysis is based on data from the Centers for 
Medicare and Medicaid Services (CMS) for the 47 unique, national stand-alone PDPs offered in
2008, representing 88 percent of all PDPs nationwide.  
HIGHLIGHTS AND KEY FINDINGS
PLAN AVAILABILITY
The number of stand-alone prescription drug plans available in 2008 (excluding the
territories) is 1,824.  About a quarter of all PDPs in 2008 are “benchmark” plans for 
the low-income subsidy (LIS); that is, they qualify to enroll beneficiaries receiving 
the full LIS with no monthly premium payment required. 
o The number of PDPs remained
relatively steady between 2007
and 2008, after a sharp increase
between 2006 and 2007 (Exhibit
1). The number of PDPs
available in 2008 varies across
regions, from a low of 47 in
Alaska to a high of 63 in the
region covering Pennsylvania and
West Virginia.
o The number of benchmark plans 
available to LIS beneficiaries is
higher in 2008 than it was in
2006, although there has
been some turnover in the
availability of these plans from
year to year, creating instability
for some LIS beneficiaries.
Beginning in 2007, CMS
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NOTE: Excludes PDPs in the territories.
SOURCE: Georgetown/NORC analysis of data from CMS for the Kaiser Family Foundation.
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implemented a policy that limited somewhat the number of LIS recipients who would need 
to switch plans because their plan no longer qualified as a benchmark plan.4  However, over 
2 million beneficiaries were reassigned to new plans in 2008. 
o The number of LIS benchmark plans varies considerably across regions in 2008, ranging 
from a low of two benchmark plans available in Nevada to a high of 19 benchmark plans 
available in Illinois. 
PREMIUMS
¾ Monthly PDP premiums vary widely in 2008, as in previous years, and are 
substantially higher for plans offering some gap coverage.  On average, enrollees who 
stayed with the same drug plan between 2007 and 2008 faced higher premiums in 
2008.    
o Monthly premiums for stand-alone Part D plans range widely, in part because different plans 
offer different benefits.5  Yet even among the stand-alone drug plans offering actuarially 
equivalent basic benefits, premiums vary from a low of $9.80 per month to a high of $72.00 
per month. 
o Enrollees in stand-alone Part D 
plans tend to pay substantially 
higher premiums for gap 
coverage.  On average, the 
unweighted monthly premium for 
a stand-alone PDP offering some 
gap coverage is twice as much as 
the monthly premium for plans 
offering an enhanced benefit, but 
no gap coverage (Exhibit 2). 
o The weighted average premium 
for stand-alone Part D coverage 
rose from $25.93 in 2006 to 
$27.39 in 2007 (Exhibit 2).  If all 
PDP enrollees remained in the 
same plan from 2007 to 2008, 
rather than switch to a different 
drug plan, the average monthly premium (weighted by enrollment) would increase from 
$27.39 to $31.99, a 17 percent increase, with nearly one in five 2007 PDP enrollees 
experiencing an annual increase of at least $120.6  According to CMS data, the majority of 
enrollees elect to keep the coverage they have from one year to the next rather than switch 
plans.7
THE COVERAGE GAP
¾ In 2008, a majority of Part D plans have a gap in drug coverage (the so-called 
“doughnut hole”) in which enrollees pay 100 percent of total drug costs before 
catastrophic coverage begins.  Only a relatively small share of Part D enrollees are 
enrolled in plans that offer gap coverage.
o In 2008, the coverage gap begins after enrollees incur $2,510 in total drug costs.  (The 
coverage gap does not apply to enrollees receiving low-income subsidies, who receive 
coverage for drug costs in the gap regardless of whether their plan offers it).  In 2008, more 
than a quarter of stand-alone Part D plans and half of Medicare Advantage plans offer some 
type of gap coverage, mainly for generic drugs (Exhibit 3).   
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o Nationwide, only one stand-alone 
PDP and 17 percent of all 
Medicare Advantage drug plans 
offer coverage for at least some 
brand-name drugs in the gap.  
o A relatively small share of Part D 
enrollees are in plans that offer 
gap coverage (Exhibit 4).  From 
2006 to 2007, enrollment in PDPs 
with any gap coverage increased 
modestly from 6 percent to 8 
percent, while enrollment in PDPs 
that offered gap coverage of both 
brands and generics decreased 
from 3 percent to 0.5 percent.  
Among MA-PD plans, in which 
nearly one-third of all Part D 
beneficiaries are enrolled, 
enrollment in plans offering gap 
coverage increased from 27 
percent to 33 percent, and the 
share with coverage of both 
brand and generics rose slightly 
from 4 percent to 6 percent. 
o Even when Part D plans offer 
some gap coverage, that 
coverage tends to be limited to 
either generic drugs only or to 
generics plus a limited set of 
brand-name drugs.  New among 
Part D plans in 2008 is the wide 
variation in the scope of benefits 
offered in the gap and the more 
limited scope of gap coverage 
even for generic drugs.  About 
half of the PDPs with gap 
coverage in 2008 do not cover all 
generics, but rather describe their plans as covering only “preferred” or “some” generics.  
The increase in the share of MA-PD plans offering gap coverage is mainly among plans 
covering all generics and “some” brand-name drugs in the coverage gap. 
BENEFIT DESIGN AND COST SHARING
¾ Most stand-alone plans do not offer the defined standard benefit, and more PDPs 
have shifted to a tiered cost-sharing structure.  Cost sharing for brand-name drugs 
has increased since 2006, particularly for non-preferred brand-name drugs. 
o In 2008, as in previous years, only about 10 percent of national PDPs (5 of 47 plans) offer 
the defined standard benefit, which includes 25 percent coinsurance and a deductible.  More 
typically, PDPs eliminate the deductible and use tiered, flat dollar copayments.   
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o Cost sharing for preferred and 
non-preferred brand-name drugs 
has increased since 2006, on 
average.  Since 2006, average 
cost sharing for a 30-day supply 
of “non-preferred” brand-name 
drugs increased by 29 percent, 
from $55.36 to $71.31, while 
average cost sharing for 
“preferred” brand drugs 
increased by 11 percent, from 
$26.87 to $29.86 (Exhibit 5).  
Cost sharing for generic drugs 
has remained fairly stable since 
2006.  Plans use tiered cost 
sharing as incentives for 
enrollees to use less expensive 
generic and “preferred” brand-
name drugs.   
o Medicare Part D plans charged more in 2007, on average, for preferred and non-preferred 
brand drugs than did employer plans, and the financial incentives for drug switching (from 
non-preferred to preferred drugs and from brands to generics) appear to be stronger in 
PDPs than in employer plans (Exhibit 5).   
o Cost-sharing amounts for 
commonly used drugs vary widely 
across Part D plans in 2008, as 
they have in previous years.  For 
example, an individual with 
Alzheimer’s disease could pay 
$20 for a month’s supply of 
Aricept under one plan in 2008, 
but $107 per month under 
another (Exhibit 6).  Cost sharing 
for Nexium ranges between $20 
and $51 in plans that cover the 
drug, but can cost as much as 
$146 per month in a plan that 
does not cover Nexium on its 
formulary.  A beneficiary enrolled 
in a national PDP that does not 
cover Prevacid would pay $201 
for a month’s supply in 2008—ten 
times more than the lowest cost-sharing amount of $20 offered by a national PDP that 
covers the drug on its formulary. 
SPECIALTY TIERS
¾ Most national stand-alone drug plans use a specialty tier for high-cost medications in 
2008, and more plans are opting to charge a higher coinsurance rate for their 
specialty tier drugs.
o Specialty tiers are commonly used by Medicare drug plans for relatively expensive drugs (at 
least $600 per month in 2008), and plans are able to charge more for specialty-tier drugs 
than they typically do for preferred or non-preferred drugs. In 2008, 41 of the 47 national 
PDPs place some drugs on a specialty tier—about twice the number of plans that had a 
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specialty tier in 2006 (Exhibit 7).  The remaining plans charge coinsurance for brand-name 
drugs and do not differentiate between specialty and non-specialty drugs. 
o The number of national PDPs 
charging 33 percent coinsurance 
for specialty tier drugs has 
increased more than five-fold 
since 2006, from 4 to 21 national 
PDPs in 2008.  Cost sharing for 
drugs placed on a specialty tier is 
generally limited to 25 percent 
coinsurance, although CMS allows 
plans to have higher cost sharing 
for drugs on the specialty tier if 
offset by a lower deductible.8
o The placement of a drug on a 
specialty tier has cost 
implications for enrollees.  For 
example, if a plan covers a 
brand-name drug with a total 
monthly cost of $600, an enrollee 
might face an average flat dollar monthly copayment of $30 if the drug is covered as 
preferred, $72 if covered as non-preferred, or $180 per month if the drug is covered on a 
specialty tier with a 30 percent coinsurance rate. 
FORMULARIES AND UTILIZATION MANAGEMENT
¾ The scope of formulary coverage continues to vary widely across PDPs in 2008, with 
the greatest differences relating to the treatment of brand-name drugs.  Based on an 
analysis of coverage of a sample of 169 drugs, PDPs have increased the use of 
utilization management restrictions for on-formulary brand-name drugs.   
o Part D plan formularies typically include more drugs than CMS standards require, but 
formulary coverage varies considerably across plans, particularly for brand-name drugs.9
While some brands appear on all formularies, others are included by far fewer plans.  In 
2008, most national PDPs (91 percent) cover a vast majority (at least 90 percent) of the 
generic sample drugs, while only 28 percent of plans cover a similarly high share of brand-
name sample drugs.   
o Among ten brand-name drugs 
commonly used by Medicare 
beneficiaries, formulary coverage 
by national PDPs in 2008 varies 
(Exhibit 8).  The majority (8 of 10 
drugs) are listed on the 
formularies of all or nearly all 
national PDPs.  Yet, even if a 
drug is listed on a plan’s 
formulary, utilization 
management restrictions may 
limit a beneficiary’s access to the 
drug.  Plans may require step 
therapy or prior authorization 
before covering a drug, or may 
limit the quantity covered.  Plans 
may also place drugs on a non-
preferred tier, associated with 
higher cost sharing.  Most 
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national plans apply at least one of these restrictions to most of the top ten brand-name 
drugs; only two of the ten drugs (Aricept and Plavix, which have no clear clinical 
alternatives) are placed on a preferred tier with no utilization management restrictions by 
more than one-third of the national plans (Exhibit 8). 
o Utilization management 
restrictions are more common 
among plans in 2008 than in 
2006, with 30 percent of the 169 
sample drugs subject to some 
use restriction in 2008, up from 
20 percent in 2006 (Exhibit 9).  
Quantity limits are applied to 21 
percent of sample drugs in 2008, 
on average across the national 
PDPs, up from 12 percent in 
2006, while use of step therapy 
has doubled from 6 percent of 
sample drugs in 2006 to 12 
percent in 2008.  The average 
use of prior authorization among 
national PDPs has remained flat 
since 2006, at about 5 percent of 
sample drugs. 
CONCLUSION
Medicare Part D plans are a relatively new and important source of prescription drug coverage for a 
growing number of Medicare beneficiaries.  Findings from this analysis show relatively minimal 
change in PDP formularies since 2006, but increases in cost sharing and utilization management 
restrictions that could have important implications for beneficiaries’ access to needed medications 
and out-of-pocket expenses.  Most Medicare drug plans do not offer coverage in the “doughnut 
hole”, and those that do primarily cover generics.  Some Medicare Advantage drug plans continue 
to offer coverage for at least a limited number of brand-name drugs in the gap.  The limited 
availability of coverage for brand-name drugs in the coverage gap puts Part D enrollees at risk of 
incurring substantial costs, an increasing concern as the size of the coverage gap expands each 
year (currently in excess of $3,000).  Wide variations across Part D plans, rising premiums, and 
changes in plan offerings, benefit design, coverage and costs that occur from year to year 
underscore the importance for consumers to compare plans each year and make informed 
decisions based on the medications they take.  Ongoing monitoring activities are critical for 
assessing the extent to which Medicare beneficiaries have access to needed and affordable 
medications through Part D plans. 
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METHODS
This report synthesizes findings presented in a series of Medicare Part D 2008 Data Spotlights prepared 
by Jack Hoadley (Health Policy Institute, Georgetown University), Elizabeth Hargrave and Katie Merrell 
(NORC at the University of Chicago), and Juliette Cubanski and Tricia Neuman (Kaiser Family 
Foundation).  Additional assistance was provided by Lauren Bakios, Jennifer Thompson, and Laura 
Summer (Health Policy Institute, Georgetown University) and Kosali Simon (Cornell University). 
Some of these findings are based on the analysis of data for the 47 unique, national stand-alone PDPs 
offered by 15 organizations in 2008, representing 88 percent of all PDPs nationwide.  The organizations 
that sponsor stand-alone prescription drug plans nationally in 2008 account for 1,598 plans – 88 
percent of the 1,824 PDPs offered nationwide.  The analysis of benefit designs and formularies excludes 
the remaining 285 plans (12 percent), which are mainly local or regional plans offered in 30 or fewer 
regions, as well as prescription drug plans offered through Medicare Advantage plans. 
Data on the characteristics of plan benefits were collected primarily from the CMS “landscape file” 
released in October 2007 and the CMS Medicare Prescription Drug Plan Finder website.  In a few cases, 
these data were supplemented or verified by more detailed information collected directly from plan 
benefit summary materials and other documents on each sponsoring organization’s website.  Complete 
formulary, cost-sharing, and pricing data for drugs are also available on the Plan Finder, but the time 
demands in collecting information from the website made it impossible to collect data on all FDA-
approved drugs for the analysis included in the Data Spotlight series. 
The analysis is based on a sample of 169 prescription drugs selected to include the most commonly 
prescribed drugs and all alternative medications in some of the drug classes most commonly used by 
Medicare beneficiaries.  The sample of drugs was selected with several goals in mind: 1) including drugs 
that are among the most frequently prescribed drugs used by Medicare beneficiaries; 2) including drugs 
that belong to certain commonly prescribed drug classes; and 3) including a sub-sample of high-cost 
drugs.  Four types of data for each drug were collected from the Medicare Prescription Drug Plan Finder 
from the Medicare.gov website:  whether a drug was on plan formularies, the cost-sharing tier for each 
covered drug, whether utilization management tools (prior authorization, quantity limits, or step 
therapy) were applied, and the price for purchases at retail pharmacies. 
A detailed appendix describing the methodology used in the Medicare Part D 2008 Data Spotlight series 
is available at http://www.kff.org/medicare/med102507pkg.cfm.
1 In 2008, the defined standard benefit has a $275 deductible, 25 percent coinsurance up to an initial benefit limit, a $3,216 
coverage gap (the “doughnut hole”), and catastrophic coverage after $5,726.25 in total Part D drug costs.
2 U.S. Department of Health and Human Services (HHS), “Medicare Prescription Drug Benefit’s Projected Costs Continue to 
Drop”, January 31, 2008 (data as of January 2008). 
3 The 2008 Data Spotlight series (available at http://www.kff.org/medicare/med102507pkg.cfm) builds on two previous 
reports commissioned by the Kaiser Family Foundation that provided an in-depth look at Medicare drug plans in 2006 and 
2007.  See Hoadley et al, “An In-Depth Examination of Formularies and Other Features of Medicare Drug Plans,” Kaiser 
Family Foundation, April 2006, available at http://www.kff.org/medicare/7489.cfm; and Hoadley et al, “Benefit Design and 
Formularies of Medicare Drug Plans: A Comparison of 2006 and 2007 Offerings,” Kaiser Family Foundation, November 2006, 
available at http://www.kff.org/medicare/7589.cfm.
4 Under the “de minimis” policy, LIS beneficiaries who are enrolled in a plan losing benchmark status are allowed to stay in 
that plan and retain the full premium subsidy as long as the new monthly premium does not exceed the regional benchmark 
by more than a small (de minimis) amount ($2 in 2007 and $1 in 2008). 
5 Beneficiaries pay, on average, 25.5 percent of the cost for standard drug coverage; the federal government subsidizes the 
remaining 74.5 percent.  In 2008, more than 9 million Part D enrollees are receiving Part D low-income subsidies and do not 
pay a premium as long as they are enrolled in a benchmark plan. 
6 The weighted premium is lower than the unweighted premium because enrollment is disproportionately distributed, with 
more enrollees in lower-premium plans than higher-premium plans. 
7 According to CMS, about 3.1 million Part D enrollees, or 12 percent, switched plans between 2007 and 2008.  Of those 
who switched, 2.1 million were beneficiaries receiving the low-income subsidy who were reassigned so they would not have 
to pay a premium.  According to CMS, about six percent of all non-LIS beneficiaries who are enrolled in Part D made a 
change between 2007 and 2008.  See HHS, January 31, 2008. 
8 CMS, “Medicare Part D Manual, Chapter 6, Part D Drugs and Formulary Requirements”  March 9, 2007. 
9 Plans must list at least two drugs in every drug category and class, as well as most or all drugs in six protected classes.  
See CMS, Chapter 6, “Part D Drugs and Formulary Requirements” in the Medicare Part D Manual (http://www.cms.hhs.gov). 
